Clinical trialNCT03628209Active, not recruitingPhase 1Interventional

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment21OsteosarcomaOsteosarcoma RecurrentOsteosarcoma in ChildrenSarcoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety and efficacy of nivolumab, or nivolumab in combination with azacitidine in participants with recurrent, resectable osteosarcoma

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Mihaela M Druta, MD
H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center
Principal Investigator
clinicaltrials.gov ↗
Patrick A. Thompson, MD
University of North Carolina, Chapel Hill
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Children'S Hospital of Los Angeles, Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
Children'S Hospital of Colorado
Aurora, Colorado, United States
Connecticut Children'S Medical Center
Hartford, Connecticut, United States
Alfred I Dupont Hospital for Children
Wilmington, Delaware, United States
Shand'S Hospital for Children at the University of Florida
Gainesville, Florida, United States
Nemours Children'S Hospital
Jacksonville, Florida, United States
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Nemours Children'S Clinic
Orlando, Florida, United States
Johns Hopkins All Children'S Hospital
St. Petersburg, Florida, United States
H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center
Tampa, Florida, United States
University of Kentucky, Markey Cancer Center
Lexington, Kentucky, United States
Johns Hopkins University, Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
University of North Carolina at Chapel Hill, Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Carolina Medical Center, Levine Cancer Institute
Charlotte, North Carolina, United States
Duke Health
Durham, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →Nivolumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Oct 2019
Primary completion: 29 Dec 2024
Completion: 30 Apr 2027
Last update posted: 30 Jul 2026
Registered enrollment: 21
Registry id: NCT03628209

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.